Povorcitinib-d6

Povorcitinib-d6 (INCB54707-d6) is the deuterium labeled Povorcitinib (HY-145588) . Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) [1][2].

Product Specifications

CAS Number

[3029304-24-0]

Product Name Alternative

INCB54707-d6

UNSPSC

12352211

Target

Isotope-Labeled Compounds; JAK

Related Pathways

Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Smiles

N#CCC1(N2C=C(C3=C(C([2H])([2H])[2H])NN=C3C([2H])([2H])[2H])C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1

Molecular Formula

C23H16D6F5N7O

Molecular Weight

513.50

References & Citations

[1]Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) . Patent WO2021076124A1.|[2]Kirby JS, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023 Oct 21:S0190-9622 (23) 03037-2.